anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Problem Agitate Solution

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 26,550
Current window 20,911-20,940
Pages 885
Rows per page 30
Arc: Problem Agitate Solutionclear collectionreset all
18 30 60

Arc

20,911-20,940 of 26,550

filter-aware
01
Slide 1
Kymera | Results Presentation Deck | 63 slidesKymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Problem Identification1 hit
02
Kymera | Results Presentation Deck | 63 slidesKymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Problem Identification1 hit
03
Kymera | Results Presentation Deck | 63 slidesKymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Problem Identification1 hit
04
Kymera | Results Presentation Deck | 63 slidesKymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Problem Identification1 hit
05
The slide uses color coding to distinguish between Oncology (dark blue) and Immunology-Inflammation (orange) programs.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Agitation1 hit
06
Kymera | Results Presentation Deck | 63 slidesKymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Agitation1 hit
07
Kymera | Results Presentation Deck | 63 slidesKymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Agitation1 hit
08
Includes a table of prevalence/incidence for specific indications and a biological pathway diagram.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Agitation1 hit
09
The slide uses a dual-panel layout: left shows tumor volume reduction over time with weekly dosing; right shows PK/PD relationship highlighting the 48-hour window of STAT3 knockdown.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Agitation1 hit
10
The slide uses a process flow diagram to illustrate the transition from dose escalation to expansion cohorts.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Agitation1 hit
11
Clinical trial safety data presentation.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Agitation1 hit
12
PK parameters include Cmax, AUC, Vd, CL, and t1/2 with associated coefficients of variation.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Agitation1 hit
13
The slide validates clinical findings against preclinical models.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · AgitationLoop · Before After1 hit
14
DL = Dose Level; DLT = Dose Limiting Toxicity; SAE = Serious Adverse Event.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · AgitationLoop · Before After1 hit
15
Kymera | Results Presentation Deck | 63 slidesKymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Agitation1 hit
16
Includes a biological pathway diagram showing signaling cascades and a table of prevalence/incidence for three specific lymphoma types.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
17
Shows efficacy data (tumor volume) alongside PK/PD mechanism data (degradation over time).Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
18
The slide uses a process flow diagram to illustrate dose escalation steps (0.16 to DLX) and a table for study objectives.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
19
The slide highlights the absence of dose-limiting toxicities (DLTs) and serious adverse events (SAEs) in the initial dose cohorts.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
20
The chart shows a log-scale y-axis for plasma concentration. The table summarizes Cmax, AUCinf, Vd, CL, and t1/2 for both dose levels.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
21
The slide uses line charts for longitudinal PBMC data and a bar chart for tumor knockdown data, supported by summary tables.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
22
POM = Proof of Mechanism; PK = Pharmacokinetics; PD = Pharmacodynamics; DL = Dose Level; KD = Knockdown; DLT = Dose-Limiting Toxicity; SAE = Serious Adverse Event.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
23
Kymera | Results Presentation Deck | 63 slidesKymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
24
The slide uses a biological pathway diagram to contrast the 'scaffolding' and 'kinase' roles of IRAK4, arguing that degradation blocks both, whereas inhibitors only block the kinase role.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
25
Includes mechanism illustration, dose-response curves, and a comparative table of IC50 values.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
26
Includes a mechanism of action diagram, a market data table, and a callout box for competitive limitations.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
27
The slide outlines a multi-part clinical trial (Parts A, B, and C) with specific dosing, randomization, and outcome metrics.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
28
Kymera | Results Presentation Deck | 63 slidesKymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
29
Kymera | Results Presentation Deck | 63 slidesKymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit
30
The table uses specific clinical metrics (HS-PGA, vIGA-AD, AN count, EASI score) to characterize the study populations.Kymera | Results Presentation Deck | 63 slides · Kymera
Conference presentation Investor relations Beat · Solution1 hit